Pfizer

PFE Healthcare & Pharma 5/10 Medium Risk
5/10
— 4 → 5 over 12 weeks
Sector avg: 2.9/10
▲
Risk Score Increased
3/10 → 5/10

Risk level moved from Low Risk to Medium Risk. Score changed by 2 points as of 2026-05-25.

What changed
▲ Near-term maturity concentration: 4.6% → 6.0% (worsened)
▲ Cash coverage: 0.57x → 0.44x (worsened)

Pfizer has $64.4B in scheduled debt maturities. PFE shows cash covering only 0.4x of $3.9B in near-term maturities. DebtCanary scores PFE at 5/10, indicating moderate refinancing pressure.

Maturity Schedule

As of 2026-03-29 (latest SEC filing with maturity data). Debt actions taken after this date will only appear once SEC processes the relevant XBRL filing.
Year 1 $3.9B Year 2 $0 Year 3 $0 Year 4 $0 Year 5 $0 Beyond 5 $60.6B
Period Amount Due % of Total
Year 1 (0-12 months) $3.9B 6.0%
Year 2 (12-24 months) N/A N/A
Year 3 (24-36 months) N/A N/A
Year 4 (36-48 months) N/A N/A
Year 5 (48-60 months) N/A N/A
Beyond 5 Years $60.6B 94.0%
Total Scheduled Maturities $64.4B 100.0%

Key Metrics

Total Long-Term Debt
N/A
Near-Term (12mo)
$3.9B
Interest Coverage
N/A
Debt/Equity
0.72
Cash Coverage
0.44x
Operating Income
N/A

Score Components

Component Value Weight
Near-Term Maturity Concentration 6.0% 30%
Interest Coverage Ratio N/A 25%
Debt-to-Equity Ratio 0.72 25%
Cash Coverage of Near-Term Debt 0.44x 20%

Recent SEC Filings

Material disclosures from Pfizer's most recent EDGAR filings. 8-K item labels indicate the type of event reported.

Date Form Details
2026-05-05 10-Q Quarterly report
2026-05-05 8-K Earnings Results
2026-04-27 8-K Shareholder Vote
2026-03-12 DEFA14A Additional proxy materials
2026-03-12 DEF 14A Proxy statement
2026-02-26 10-K Annual report
2026-02-03 8-K Earnings Results
2025-12-16 8-K Reg FD Disclosure

Related Companies

Johnson & Johnson
JNJ
2/10
Debt: $41.4B 12mo: $2.0B
AbbVie
ABBV
4/10
Debt: $64.5B 12mo: $6.0B
Merck &
MRK
3/10
Debt: N/A 12mo: $2.6B
Eli Lilly
LLY
2/10
Debt: $29.5B 12mo: $781M
Bristol Myers Squibb
BMY
5/10
Debt: $44.1B 12mo: $2.0B
Amgen
AMGN
5/10
Debt: $57.3B 12mo: $4.6B
Gilead Sciences
GILD
2/10
Debt: $22.2B 12mo: $1.3B
Regeneron Pharmaceuticals
REGN
1/10
Debt: N/A 12mo: N/A

Data Source: Financial data sourced from SEC EDGAR XBRL filings (10-K annual reports). Fiscal period end: 2026-03-29. Filing date: 2026-05-05. Data last fetched: 2026-05-25. Maturity schedules reflect the company's most recently reported debt repayment obligations. Data quality: Partial.
View SEC EDGAR filings for Pfizer →